Our results provide further evidence for the mucosal protective property of LPAR2 and demonstrate for the first time that selective activation of LPAR2 by DBIBB mitigates NSAID-induced small intestinal injury, whereas lack of LPAR2 accelerates the development of enteropathy. This evidence concerns the gene LPAR2 and Abnormal intestine morphology.